BeneFix

(redirected from recombinant coagulation factor IX)

BeneFix

A recombinant factor IX for treating spontaneous bleeds (prophylaxis) and preventing bleeds during surgery and postoperatively in patients with haemophilia.

Adverse effects
Dizziness, headache, altered taste, lightheadedness, nausea, cellulitis, phlebitis, injection-site reaction, neutralising antibodies resulting in factor IX inhibition.

BeneFix®

Recombinant coagulation factor IX Hematology A recombinant factor IX for treating spontaneous bleeds, prophylaxis, and preventing bleeds during surgery and postoperatively in Pts with hemophilia B

benefix

A brand name for recombinant human Factor IX formulated as a drug.
References in periodicals archive ?
An oral presentation will focus on the pivotal trial for CSL Behring's novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) for the treatment of hemophilia B.
2 Concentrate recombinant coagulation factor IX least second generation delivered to the patient~s home / to the hemophilia treatment center.
In addition to the recombinant coagulation factor IX program, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties.
Contract notice: Concentrate recombinant coagulation factor ix least second generation, the investigation sign: zzp-156/15.
BERN, Switzerland, July 28, 2015 /PRNewswire/ -- CSL Behring announced today that Swissmedic has accepted for review a Marketing Authorization Application (MAA) for the company's investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) for the prophylaxis and treatment of bleeding episodes in people with Hemophilia B.
March 30, 2015 /PRNewswire/ -- CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
16, 2014 /PRNewswire/ -- CSL Behring announced today it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Contract award: concentrate recombinant coagulation factor ix least second generation - zzp-70/15.
Contract notice: Concentrate recombinant coagulation factor ix minimum of second-generation, handling character: zzp-70/15.
Contract notice: Concentrate recombinant coagulation factor ix at least second generation, handling character: zzp-158/14.

Full browser ?